Please assess the completion status of the following clinical trial:

Trial Title: Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~healthy male and female subjects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BI 10773/linagliptin FDC SID (Type: EXPERIMENTAL): medium single dose ofBI 10773/linagliptin FDC (Formulation A1)
- BI 10773/linagliptin SID (Type: EXPERIMENTAL): medium single dose of mono components BI 10773/linagliptin
- BI 10773/linagliptin FDC (Type: EXPERIMENTAL): medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
- BI 10773/linagliptin (Type: EXPERIMENTAL): medium single dose of BI 10773/linagliptin FDC (Formulation A3)

Based on this trial design, predict the completion outcome and termination type (if applicable).